Skip to main content
Noxxon, German center to collaborate on cancer trial

The National Center for Tumor Diseases in Germany has entered into an agreement with Noxxon Pharma to conduct a Phase I/II study of Noxxon's Spiegelmer drug candidate NOX-A12, or olaptesed pegol, and Merck's Keytruda, or pembrolizumab. The drugs are being developed for metastatic pancreatic and colorectal cancer indications.

Full Story: